These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 30753197

  • 1. Toxoplasmic retinochoroiditis: The influence of age, number of retinochoroidal lesions and genetic polymorphism for IFN-γ +874 T/A as risk factors for recurrence in a survival analysis.
    Aleixo ALQDC, Vasconcelos C de Oliveira R, Cavalcanti Albuquerque M, Biancardi AL, Land Curi AL, Israel Benchimol E, Reis Amendoeira MR.
    PLoS One; 2019; 14(2):e0211627. PubMed ID: 30753197
    [Abstract] [Full Text] [Related]

  • 2. Toxoplasmic Retinochoroiditis: Clinical Characteristics and Visual Outcome in a Prospective Study.
    Aleixo AL, Curi AL, Benchimol EI, Amendoeira MR.
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004685. PubMed ID: 27136081
    [Abstract] [Full Text] [Related]

  • 3. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis.
    Silveira C, Belfort R, Muccioli C, Holland GN, Victora CG, Horta BL, Yu F, Nussenblatt RB.
    Am J Ophthalmol; 2002 Jul; 134(1):41-6. PubMed ID: 12095806
    [Abstract] [Full Text] [Related]

  • 4. Associations between Polymorphisms within Interferon Gamma and Tumor Necrosis Factor Genes and Toxoplasma Retinochoroiditis in Ghanaian Patients.
    Abu EK, Boampong JN, Kyei S, Afoakwah R, Ayi I.
    Ocul Immunol Inflamm; 2017 Oct; 25(5):678-684. PubMed ID: 27081842
    [Abstract] [Full Text] [Related]

  • 5. The IFN-gamma +874T/A gene polymorphism is associated with retinochoroiditis toxoplasmosis susceptibility.
    Albuquerque MC, Aleixo AL, Benchimol EI, Leandro AC, das Neves LB, Vicente RT, Bonecini-Almeida Mda G, Amendoeira MR.
    Mem Inst Oswaldo Cruz; 2009 May; 104(3):451-5. PubMed ID: 19547871
    [Abstract] [Full Text] [Related]

  • 6. Trimethoprim-Sulfamethoxazole Versus Placebo in Reducing the Risk of Toxoplasmic Retinochoroiditis Recurrences: A Three-Year Follow-up.
    Fernandes Felix JP, Cavalcanti Lira RP, Cosimo AB, Cardeal da Costa RL, Nascimento MA, Leite Arieta CE.
    Am J Ophthalmol; 2016 Oct; 170():176-182. PubMed ID: 27521607
    [Abstract] [Full Text] [Related]

  • 7. Clinical and Biological Factors Associated With Recurrences of Severe Toxoplasmic Retinochoroiditis Confirmed by Aqueous Humor Analysis.
    Matet A, Paris L, Fardeau C, Terrada C, Champion E, Fekkar A, Cassoux N, Touitou V, LeHoang P, Bodaghi B.
    Am J Ophthalmol; 2019 Mar; 199():82-93. PubMed ID: 30502335
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Recurrent toxoplasmic retinochoroiditis. Significance of perilesional satellite dark dots seen by indocyanine green angiography.
    Bernasconi O, Auer C, Herbort CP.
    Ocul Immunol Inflamm; 1997 Sep; 5(3):207-11. PubMed ID: 9326766
    [Abstract] [Full Text] [Related]

  • 11. Long-term Results of Trimethoprim-Sulfamethoxazole Versus Placebo to Reduce the Risk of Recurrent Toxoplasma gondii Retinochoroiditis.
    Fernandes Felix JP, Cavalcanti Lira RP, Grupenmacher AT, Assis Filho HLG, Cosimo AB, Nascimento MA, Leite Arieta CE.
    Am J Ophthalmol; 2020 May; 213():195-202. PubMed ID: 31926883
    [Abstract] [Full Text] [Related]

  • 12. Antibiotics for toxoplasmic retinochoroiditis: an evidence-based systematic review.
    Stanford MR, See SE, Jones LV, Gilbert RE.
    Ophthalmology; 2003 May; 110(5):926-31; quiz 931-2. PubMed ID: 12750091
    [Abstract] [Full Text] [Related]

  • 13. Immune Mediators against Toxoplasma Gondii during Reactivation of Toxoplasmic Retinochoroiditis.
    Rudzinski M, Argüelles C, Couto C, Oubiña JR, Reina S.
    Ocul Immunol Inflamm; 2019 May; 27(6):949-957. PubMed ID: 30081671
    [Abstract] [Full Text] [Related]

  • 14. Presumed toxoplasmic retinochoroiditis in four siblings.
    Asbell PA, Vermund SH, Hofeldt AJ.
    Am J Ophthalmol; 1982 Nov; 94(5):656-63. PubMed ID: 7148946
    [Abstract] [Full Text] [Related]

  • 15. Frequency and factors associated with recurrences of ocular toxoplasmosis in a referral centre in Colombia.
    de-la-Torre A, Rios-Cadavid AC, Cardozo-García CM, Gomez-Marín JE.
    Br J Ophthalmol; 2009 Aug; 93(8):1001-4. PubMed ID: 19429576
    [Abstract] [Full Text] [Related]

  • 16. [Interest in treatment with subconjunctival clindamycin in toxoplasmic retinochoroiditis].
    Ben Zina Z, Abid D, Kharrat W, Chaker N, Aloulou K, Chaâbouni M.
    Tunis Med; 2001 Mar; 79(3):157-60. PubMed ID: 11471444
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Interleukin-1 gene polymorphisms and toxoplasmic retinochoroiditis.
    Cordeiro CA, Moreira PR, Costa GC, Dutra WO, Campos WR, Oréfice F, Teixeira AL.
    Mol Vis; 2008 Mar; 14():1845-9. PubMed ID: 18941541
    [Abstract] [Full Text] [Related]

  • 19. TNF-alpha gene polymorphism (-308G/A) and toxoplasmic retinochoroiditis.
    Cordeiro CA, Moreira PR, Costa GC, Dutra WO, Campos WR, Oréfice F, Teixeira AL.
    Br J Ophthalmol; 2008 Jul; 92(7):986-8. PubMed ID: 18577652
    [Abstract] [Full Text] [Related]

  • 20. [Efficacy of specific chemotherapy in the prevention of recurrences of toxoplasmic chorioretinitis during the 4 years following the treatment].
    Timsit JC, Bloch-Michel E.
    J Fr Ophtalmol; 1987 Jul; 10(1):15-23. PubMed ID: 3598056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.